Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors

Cancer Genetics and Cytogenetics

Volumn 146, Issue 1, 2003, Pages 33-40

  Cavalli, Luciane R ^a   Urban, Cícero A ^b   Dai, Dongqiu ^c   De Assis, Sônia ^a   Tavares, Denise C ^d   Rone, Janice D ^a   Bleggi Torres, Luiz F ^e   Lima, Rubens S ^b   Cavalli, Iglenir J ^e   Issa, Jean Pierre J ^c   Haddad, Bassem R ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSIDADE DE FRANCA   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CHROMOSOME 11P; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 9Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MEASUREMENT; METHYLATION; MUTATION; OBSERVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE;

EID: 0141565167     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(03)00123-7     Document Type: Article

References (41)

1. Hermsen M.A., Baak J.P., Meijer G.A., Weiss J.M., Walboomers J.W., Snijders P.J., van Diest P.J. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric and DNA cytometric prognostic factors. J Pathol. 186:1998;356-362.
2. Lindahl T., Engel G., Ahlgren J., Klaar S., Bjohle J., Lindman H., Andersson J., von Schoultz E., Bergh J. Can axillary dissection be avoided by improved molecular biological diagnosis? Acta Oncol. 39:2000;319-326.
3. Reintgen D., Giuliano R., Cox C.E. Sentinel node biopsy in breast cancer: an overview. The Breast Journal. 6:2000;299-305.
4. Giuliano A.E. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J Surg Oncol. 62:1996;75-77.
5. Veronesi U., Paganelli G., Viale G., Galimberti V., Luini A., Zurrida S., Robertson C., Sacchini V., Veronesi P., Orvieto E., De Cicco C., Intra M., Tosi G., Scarpa D. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 91:1999;368-373.
6. Breslin T.M., Cohen L., Sahin A., Fleming J.B., Kuerer H.M., Newman L.A., Delpassand E.S., House R., Ames F.C., Feig B.W., Ross M.I., Singletary S.E., Buzdar A.U., Hortobagyi G.N., Hunt K.K. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 18:2000;3480-3486.
7. Veronesi U., Galimberti V., Zurrida S., Pigatto F., Veronesi P., Robertson C., Paganelli G., Sciascia V., Viale G. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer. 37:2001;454-458.
8. Ollila D.B., Stitzenberg K.B. Breast cancer sentinel node metastases: histopathologic detection and clinical significance. Cancer Control. 8:2001;407-414.
9. Pandis N., Bardi G., Jin Y., Dietrich C., Johansson B., Andersen J., Mandahl N., Mitelman F., Heim S. Unbalanced t(1;16) as the sole karyotypic abnormality in a breast carcinoma and its lymph node metastasis. Cancer Genet Cytogenet. 75:1994;158-159.
10. Teixeira M.R., Pandis N., Gerdes A.M., Dietrich C.U., Bardi G., Andersen J.A., Graversen H.P., Mitelman F., Heim S. Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. Breast Cancer Res Treat. 38:1998;177-182.
11. Bernardino J., Gerbault-Seureau M., Sastre X., Dutrillaux B. Unusual clonal chromosomal evolution in a breast carcinoma and its lymph node metastasis in a patient with Down syndrome. Genes Chromosomes Cancer. 19:1997;195-199.
12. Nishizaki T., DeVries S., Chew K., Goodson W.H. 3rd, Ljung B.M., Thor A., Waldman F.M. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer. 19:1997;267-272.
13. Pandis N., Teixeira M.R., Adeyinka A., Rizou H., Bardi G., Mertens F., Andersen J.A., Bondeson L., Sfikas K., Qvist H., Apostolikas N., Mitelman F., Heim S. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer. 22:1998;122-129.
14. Kuukasjarvi T., Karhu R., Tanner M., Kahkonen M., Schaffer A., Nupponen N., Pennanen S., Kallioniemi A., Kallioniemi O.P., Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57:1997;1597-1604.
15. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
16. Figueiredo B.C., Stratakis C.A., Sandrini R., DeLacerda L., Pianovsky M.A., Giatzakis C., Young H.M., Haddad B.R. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metabol. 84:1999;1116-1121.
17. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:1996;9821-9826.
18. Xiong Z., Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25:1997;2532-2534.
19. Widschwendter M., Jones P.A. DNA methylation and breast carcinogenesis. Oncogene. 21:2002;5462-5482.
20. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 96:1999;8681-8686.
21. Bell K.A., Van Deerlin P.G., Feinberg R.F., du Manoir S., Haddad B.R. Diagnosis of aneuploidy in archival, paraffin embedded pregnancy-loss tissues by comparative genomic hybridization. Fertil Steril. 75:2001;374-379.
22. Clark S.J., Harrison J., Paul C.L., Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22:1994;2990-2997.
23. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A., Issa J.P. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 94:2002;755-761.
24. Van Diest P.J., Torrenga H., Borgstein P.J., Pijpers R., Bleichrodt R.P., Rahusen F.D., Meijer S. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer. Histopathology. 35:1999;14-18.
25. Pendas S., Dauway E., Cox C.E., Giuliano R., Ku N.N., Schreiber R.H., Reintgen D.S. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg. 65:1999;500-505.
26. Manzotti M., Dell'Orto P., Maisonneuve P., Zurrida S., Mazzarol G., Viale G. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer. 95:2001;307-312.
27. Veronesi U., Paganelli G., Viale G., Galimberti V., Luini A., Zurrida S., Robertson C., Sacchini V., Veronesi P., Orvieto E., De Cicco C., Intra M., Tosi G., Scarpa D. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 349:1997;1864-1867.
28. Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 220:1994;391-398.
29. Giuliano A.E., Jones R.C., Brennan M., Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 15:1997;2345-2350.
30. Thor A.D., Berry D.A., Budman D.R., Muss H.B., Kute T., Henderson I.C., Barcos M., Cirrincione C., Edgerton S., Allred C., Norton L., Liu E.T. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 90:1998;1346-1360.
31. Linderholm B., Tavelin B., Grankvist K., Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol. 16:1998;3121-3128.
32. Forozan F., Karhu R., Kononen J., Kallioniemi A., Kallioniemi O.P. Genome screening by comparative genomic hybridization. Trends Genet. 13:1997;405-409.
33. Toyota M., Issa J.P. Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. Methods Mol Biol. 200:2002;101-110.
34. Pandis N., Teixeira M.R., Gerdes A.M., Limon J., Bardi G., Andersen J.A., Idvall I., Mandahl N., Mitelman F., Heim S. Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. Cancer. 76:1995;250-258.
35. Dutrillaux B., Gerbault-Seureau M., Zafrani B. Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet. 49:1990;203-217.
36. Pandis N., Heim S., Bardi G., Idvall I., Mandahl N., Mitelman F. Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. Genes Chromosomes Cancer. 5:1992;235-238.
37. Tsuda H., Callen D.F., Fukutomi T., Nakamura Y., Hirohashi S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res. 54:1994;513-517.
38. Leder A., Pattengale P.K., Kuo A., Stewart T.A., Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell. 45:1986;485-495.
39. Watson P.H., Pon R.T., Shiu R.P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51:1991;3996-4000.
40. Berns E.M., Foekens J.A., van Staveren I.L., van Putten W.L., de Koning H.Y., Portengen H., Klijn J.G. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 14:1995;11-18.
41. Garcia-Manero G., Bueso-Ramos C., Daniel J., Williamson J., Kantarjian H.M., Issa J.P. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 8:2002;1897-1903.